Royce & Associates LP lifted its stake in shares of Enovis Corporation (NYSE:ENOV – Free Report) by 14.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 826,848 shares of the company’s stock after purchasing an additional 105,608 shares during the period. Royce & Associates LP’s holdings in Enovis were worth $22,027,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Allspring Global Investments Holdings LLC lifted its position in shares of Enovis by 11.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company’s stock worth $20,086,000 after purchasing an additional 78,497 shares in the last quarter. Impax Asset Management Group plc lifted its position in shares of Enovis by 47.5% during the third quarter. Impax Asset Management Group plc now owns 310,630 shares of the company’s stock worth $9,425,000 after purchasing an additional 100,000 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Enovis by 2.0% during the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock worth $197,945,000 after purchasing an additional 125,460 shares in the last quarter. Deroy & Devereaux Private Investment Counsel Inc. acquired a new position in shares of Enovis during the fourth quarter worth approximately $2,929,000. Finally, Public Sector Pension Investment Board lifted its position in shares of Enovis by 14.5% during the third quarter. Public Sector Pension Investment Board now owns 222,939 shares of the company’s stock worth $6,764,000 after purchasing an additional 28,236 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, insider Oliver Engert bought 1,000 shares of the stock in a transaction on Friday, February 27th. The stock was purchased at an average price of $25.50 per share, with a total value of $25,500.00. Following the completion of the purchase, the insider owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have purchased a total of 5,000 shares of company stock valued at $121,983 over the last ninety days. 2.90% of the stock is currently owned by corporate insiders.
Enovis Stock Up 0.5%
Enovis (NYSE:ENOV – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the prior year, the firm earned $0.81 earnings per share. The business’s quarterly revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts forecast that Enovis Corporation will post 3.65 earnings per share for the current year.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on ENOV. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a report on Sunday, May 10th. BTIG Research restated a “buy” rating and issued a $39.00 price objective on shares of Enovis in a report on Friday, May 22nd. Wells Fargo & Company cut their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Evercore restated an “outperform” rating and issued a $36.00 price objective on shares of Enovis in a report on Friday, May 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.50.
View Our Latest Analysis on Enovis
Enovis Profile
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
See Also
- Five stocks we like better than Enovis
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV – Free Report).
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
